Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol PRKACA contributors: mct/shn - updated : 05-10-2015
HGNC name protein kinase, cAMP-dependent, catalytic, alpha
HGNC id 9380
Location 19p13.2      Physical location : 14.202.508 - 14.228.559
Synonym name
  • PKA C-alpha
  • protein kinase A catalytic subunit
  • Synonym symbol(s) MGC102831, MGC48865, PKACa, Cs, PKA, PKCD
    TYPE functioning gene
    STRUCTURE 26.06 kb     10 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    MAPPING cloned Y linked   status provisional
    Map pter - D19S914 - D19S840 - PRKACA - D19S892 - D19S226 - cen
    Physical map
    MGC10471 19p13.13 hypothetical protein MGC10471 MGC3207 19p13.13 hypothetical protein MGC3207 HSPC023 19p13.13 HSPC023 protein ZSWIM4 19p13.13 zinc finger, SWIM domain containing 4 NANOS3 19p13.13 nanos homolog 3 (Drosophila) MGC11271 19p13.13 hypothetical protein MGC11271 FLJ20241 19p13.13 putative NFkB activating protein FLJ23447 19p13.13 hypothetical protein FLJ23447 LOC90379 19p13.13 hypothetical protein BC002926 RFX1 19p13.1 regulatory factor X, 1 (influences HLA class II expression) RLN3 19p13.2 relaxin 3 (H3) WSX1 LOC342979 19p13.13 hypothetical LOC342979 LOC126037 19p13.13 similar to eukaryotic translation elongation factor 1 delta isoform 1; guanine nucleotide exchange protein LOC113230 19p13.13 hypothetical protein LOC113230 PRKACA 19p13.1 protein kinase, cAMP-dependent, catalytic, alpha ASF1B 19p13.12 ASF1 anti-silencing function 1 homolog B (S. cerevisiae) LPHN1 19p13.2 latrophilin 1 CD97 19p13.2-p13.12 CD97 antigen DDX39 19p13.13 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 PRKCL1 19p13.1-p12 protein kinase C-like 1 PTGER1 19p13.1 prostaglandin E receptor 1 (subtype EP1), 42kDa RGS19IP1 19p13.2-p13.1 regulator of G-protein signalling 19 interacting protein 1 DNAJB1 19p13.2 DnaJ (Hsp40) homolog, subfmaily B, member 1 GPSN2 19p13.12 glycoprotein, synaptic 2 NDUFB7 19p13.12-p13.11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa LOC388512 19 similar to Asialoglycoprotein receptor 2 (Hepatic lectin H2) (ASGP-R) (ASGPR) EMR3 19p13.1 egf-like module containing, mucin-like, hormone receptor-like 3 ZNF333 19p13 zinc finger protein 333 EMR2 19p13.1 egf-like module containing, mucin-like, hormone receptor-like sequence 2 OR7C1 19p13.1 olfactory receptor, family 7, subfamily C, member 1 OR7A5 19p13.1 olfactory receptor, family 7, subfamily A, member 5 pseudogene
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    10 - 2689 - 351 - 1996 8884279
    10 - 2490 - 343 - 1996 8884279
    Type ubiquitous
       expressed in (based on citations)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Cardiovascularheart   highly
    Reproductivefemale systembreastmammary gland highly
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    cell lineage
    cell lines
    at STAGE
    a N terminus segment involved in the sensitivity to dequalinium
    interspecies ortholog to Prkaca, Rattus norvegicus
    ortholog to Prkaca, Mus musculus
    FAMILY PRK family
    CATEGORY enzyme
        plasma membrane
    text PRKACA is localized at the leading edge of membrane protrusions and colocalized with WASF2
    basic FUNCTION
  • involved in the regulation of AICDA function and in the control of T cell-dependent immune responses modulated, via AICDA, by signals that activate PRKACA
  • phosphorylating AICDA and regulating its activity in germinal center B cells
  • its activation is both necessary and sufficient to trigger irreversible growth arrest during keratinocyte differentiation
  • critical role for its signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors CDKN1A, CDKN1B and activation of AKT1 and ERK-dependent proliferative pathways
  • can negatively regulate ESR1, at least in part, through FOXH1
  • key component that controls MYD88-dependent cytokine gene expression in human and mouse but differentially regulates production of TRIF-dependent cytokines
  • affects cell cycle progression and proliferation in human RPE cells through the downregulation of CDKN1B
  • PKCalpha-dependent stimulation of arginine transport requires the activation of MEK/ERK1/2 cascade, which leads to the stimulation of AP-1 and to the consequent induction of SLC7A2 expression
  • plays an important role in redistributing GluN2BR at synapses and pain hypersensitivity (
  • enhances the osteogenic function of DLX5, at least in part, through protein stabilization
  • novel role of PRKACA in the regulation of RCAN1 activity through phosphorylation
  • AKAP1-PRKACA-PDE4A distribution and integrity have a key role in cellular survival
  • PRKACA directly phosphorylates ATR at Ser435, which actively recruits the key NER protein xeroderma pigmentosum complementation group A (XPA)
    a component
  • PRKACA, AKT1 and RAPGEF3 were all shown to establish complexes with neuronal A-kinase anchoring protein 150 (AKAP5)
  • WASF2-PRKACA complex is potentially localized at membrane protrusions
    small molecule
  • Grb2 and EGF-receptor (
  • A-kinase-anchoring proteins (AKAPs) (
  • PKA-interacting protein, AKIP1 (
  • AKAP12 target PRKACA and other binding partners to the plasma membrane
  • interactions between endogenous RPS6KA1 and PKAc in intact cells regulate the ability of cAMP to activate PRKACA
  • PRKACA interacts directly with HDAC5 and phosphorylates HDAC5 at serine 280, an evolutionarily conserved site
  • interaction with WASF2 (WASF2 is necessary for the localization of PRKACA under quiescent conditions as well as for membrane protrusions induced by PRKACA activation)
  • interacting with DLX5 (phosphorylates DLX5 and PRKACA activation increases the protein stability, osteogenic activity and transcriptional activity of DLX5)
  • PJA2 forms a stable complex with, and is phosphorylated by PRKACA
  • interplay between PRKACA phosphorylation and TAL1-mediated epigenetic regulation that regulates hematopoietic transcription and differentiation programs during hematopoiesis and leukemogenesis
  • AKAP13 may serve an ancillary cardioprotective role by favouring the association of PRKACA with HSPB6
  • PRKACA and PDE4D anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome
  • direct anchoring of both PRKACA and ADCY1 to TRPV1 by AKAP5 facilitates the response to inflammatory mediators and may be critical in the pathogenesis of thermal hyperalgesia
  • WEE2 acts as a direct downstream substrate of protein kinase A (PRKACA)
  • anchoring of not only PRKACA but also ADCY1 by AKAP5 is important for regulation of postsynaptic functions and specifically AMPA receptor activity
  • DLX3 is a novel target of PRKACA, and PRKACA mediates BMP signaling during osteoblast differentiation, at least in part, by phosphorylating DLX3 and modulating the protein stability and function of DLX3
  • IMMT is a PRKACA substrate
  • cell & other
  • ciliary axonemes (
    activated by phorbol esters or thymeleatoxin which causes a transient increase of arginine transport through system y(+), referable to the induction of SLC7A2 mRNAs and to the increased expression of SLC7A2 transporters
    ABCA1 that activates PRKACA
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --low  
    in colorectal cancers with constitutive activation of the Wnt-APC pathway
    tumoral somatic mutation      
    in hypothalamic hamartoma with gelastic epilepsy
    tumoral fusion      
    DNAJB1-PRKACA fusion gene characterizeshepatocellular fibrolamellar carcinoma
    Variant & Polymorphism
    Candidate gene
  • marker for poor prognosis of breast cancer and correlates to and is important for cell functions associated with breast cancer progression
  • Therapy target
  • hippocampal PKA inhibition by infusion of Rp-cAMPS restored long-term memory in R6/2 mice
  • SystemTypeDisorderPubmed
    targeting PRKACA may provide novel therapeutic options in endometrial tumors
    inhibition of PKA activation, together with standard AR-targeted therapies, may be more efficacious for treatment of patients with prostate cancer
  • hippocampal cAMP-dependent protein kinase (PKA) hyper-activation in na
  • ve R6/1 mice compared with wild-type (WT) mice, whereas extracellular signal-regulated kinase 1/2 and calcineurin activities were not modified